Insulin aspart
Also known as: Asp(B28) insulin, Fiasp, IAsp, Insulin aspart, NovoLog, NovoRapid
Source Insulin aspart at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Rapid-acting insulin analog used to control blood glucose in type 1 and type 2 diabetes mellitus.
Mechanism of Action
Activates the insulin receptor tyrosine kinase, enhancing glucose uptake and metabolism
Routes of Administration
Goals & Uses
- Diabetic ketoacidosis treatment (IV)Emergency Glycemic ManagementModerate
- Type 2 diabetes mellitus managementGlycemic ManagementHigh
- Glycemic controlDiabetesHigh
- Type 1 diabetes mellitus managementGlycemic ManagementHigh
- Gestational diabetes / diabetes in pregnancyGlycemic ManagementHigh
- Postprandial glucose controlGlycemic ManagementHigh
Contraindications
- Known hypersensitivity to insulin aspart or excipientsAllergicHigh
- Hypersensitivity to insulin aspart or excipientsImmunologicHigh
- Hypoglycemia (active episode)MetabolicHigh
- HypoglycemiaMetabolicHigh
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
- Injection site reactionsLocalCommon
- Allergic reactions / anaphylaxisImmunologicRare
- Weight gainMetabolicCommonIncrease in body weight
- LipodystrophyDermatologicUncommon
Drug Interactions
- Thiazolidinediones (e.g., pioglitazone)Moderate
- Salicylates (high-dose aspirin)Low
- Beta-blockersModerate
- AlcoholModerate
- CorticosteroidsModerate
- MAO inhibitorsModerate
- ACE inhibitorsLow
Population Constraints
- Pediatrics (<6 years)AgeRelative
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMarketed as NovoRapid
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMarketed as NovoLog
- United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusAvailable under NHS formularies
Approved in US (FDA), EU (EMA), and many other jurisdictions; indicated for mealtime insulin therapy.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Insulin aspart?
Rapid-acting insulin analog used to control blood glucose in type 1 and type 2 diabetes mellitus.
What is Insulin aspart used for?
Insulin aspart is educationally associated with: Diabetic ketoacidosis treatment (IV), Type 2 diabetes mellitus management, Glycemic control, Type 1 diabetes mellitus management, Gestational diabetes / diabetes in pregnancy, Postprandial glucose control. Educational only — not medical advice.
How is Insulin aspart administered?
Recorded routes of administration: Continuous Subcutaneous Infusion (insulin Pump), Intravenous, Subcutaneous.
What are the potential side effects of Insulin aspart?
Reported adverse effects include: Hypokalemia, Hypoglycemia, Peripheral edema, Injection site reactions, Allergic reactions / anaphylaxis, Weight gain, Lipodystrophy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin aspart?
Recorded contraindications: Known hypersensitivity to insulin aspart or excipients, Hypersensitivity to insulin aspart or excipients, Hypoglycemia (active episode), Hypoglycemia. Consult a qualified clinician before use.